Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 12, 2023, titled "APL Healthcare receives USFDA Approval for Sevelamer Hydrochloride Tablets 400 mg and 800 mg.".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 12, 2023, titled "APL Healthcare receives USFDA Approval for Sevelamer Hydrochloride Tablets 400 mg and 800 mg.".